Skinfix is gearing as much as launch its first treatment for psoriasis-prone skin, a notoriously hard condition to treat.

Skinfix’s KP & PsO Smoothing Body Treatment, a every day skin treatment for each psoriasis and keratosis pilaris, will debut mid-June at Sephora, priced at $50.

“Our Resurface⁺ Scrub and Cream that help address KP have consistently been two of our bestselling products at Sephora,” said Amy Gordinier, Skinfix founder and chief executive officer. “Based on our ongoing commitment to healing skin, including KP, and research showing psoriasis as a growing concern, we developed the brand new Resurface⁺ KP + PsO Smoothing Body Treatment to handle each conditions.”

In response to the National Psoriasis Foundation, psoriasis affects greater than 3 percent of the U.S. adult population, the similar to around 7.5 million adults. Statistics from the National Institutes of Health showed that for KP, probably the most common patient population is adolescents, with 50 to 80 percent affected.

Gordinier told Beauty Inc that the product was two years within the making and formulated with dermatologist and Skinfix scientific advisory board member, Dr. Peter Lio.

“Through our work with dermatologists, we’ve learned that psoriasis will be difficult to treat and we wanted to make sure the precise combination of clinical actives to focus on this difficult skin condition together with the derm-evaluated clinical results to prove the product works,” she added. 

Each psoriasis and keratosis pilaris are brought on by hyper-keratinization, an overproduction of skin cells.  As a substitute of exfoliating with one high-percentage acid, Skinfix’s KP & PsO Smoothing Body Treatment delivers a mix of clinical actives including emollients and chemical exfoliants like AHAs & BHAs for exfoliation, smoothing and brightening, in addition to barrier-restorative actives. 

“While very different, [keratosis pilaris and psoriasis] share a key aspect: they each have an overabundance of keratin, known as ‘hyperkeratosis’,” Lio said. “We proceed to search for topical agents that may reduce this keratin buildup but can accomplish that in a delicate, supportive manner slightly than being overly harsh. The brand new KP + PsO Smoothing Body Treatment manages to string the needle here: a robust moisturizer that may soften and smooth the skin with the very best of them, yet gentle enough to make use of every day without causing irritation.”

Nova Scotia, Canada-based Skinfix was founded by Gordinier in 2014 as a line meant to heal and maintain the skin barrier and has been a frontrunner within the rise of clinical skincare. The corporate began with products specifically formulated around eczema, and has since expanded to several types of products for face and body. 

Skinfix’s key products include the Barrier+ Triple Lipid-Peptide line, in addition to Resurface+ line, which incorporates chemical exfoliation products. 

In 2021, it secured a minority investment from private-equity firm Stride Consumer Partners. Terms of the investment weren’t disclosed, but industry sources on the time estimated Skinfix was approaching $25 million in net sales.